Compare · GPUS vs TMO
GPUS vs TMO
Side-by-side comparison of Hyperscale Data Inc. (GPUS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- GPUS operates in Technology, while TMO operates in Industrials - the two are in different parts of the market.
- TMO carries a market cap of $225.41B.
- GPUS has been more active in the news (15 items in the past 4 weeks vs 6 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 0 for GPUS).
- Company
- Hyperscale Data Inc.
- Thermo Fisher Scientific Inc
- Price
- $0.16+0.84%
- $469.57+0.63%
- Market cap
- -
- $225.41B
- 1M return
- +1.76%
- -
- 1Y return
- -89.75%
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- 1997
- News (4w)
- 15
- 6
- Recent ratings
- 0
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest GPUS
- Hyperscale Data Sees Rising Demand Across Defense Portfolio Amid Heightened Global Activity
- Hyperscale Data Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Hyperscale Data Exceeds $50 Million in Bitcoin Holdings for Second Time, Surpassing Halfway Mark Toward $100 Million Bitcoin Treasury Goal
- Hyperscale Data Accelerates Michigan Operations Capabilities for AI Data Center and Robotics Hub
- Hyperscale Data Issues Strategic Statement by Its Executive Chairman on Omnipresent Robotics and U.S. Based Robotics Infrastructure and Embodied AI Development
- Hyperscale Data Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock
- Hyperscale Data Announces Strategic Partnership with AGIBOT for AI Robotics
- Hyperscale Data to Host Conference Call on April 21, 2026 to Provide Michigan AI Data Center Campus Update
- SEC Form 10-K filed by Hyperscale Data Inc.
Latest TMO
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026
- SEC Form 4 filed by Sperling Scott M
- SEC Form 4 filed by Keith R. Alexandra
- SEC Form 4 filed by Lynch Karen S